Novartis Eyes $1B Sales With Fda Nod For Targeted Sickle Cell Disease Drug Adakveo
Another Candidate For Novartis' Future Blockbuster Club Is Here.Friday, The Swiss Drugmaker Won Fda Approval For Adakveo, The First Targeted Therapy To Prevent The Painful Vaso-Occlusive Crises (Vocs) That Come Along With Sickle Cell Disease. The Nod Came Weeks Ahead Of Schedule, Even On Top Of A Priority Review Doled Out In July.Novartis Has Priced The New Drug, Meant For Patients 16 And Older, At A Wholesale Acquisition Cost (Wac) Of $2,357 Per Vial. As It
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!